Intercept to Present at Upcoming Investor Conferences in September
Get Alerts ICPT Hot Sheet
Join SI Premium – FREE
NEW YORK, Aug. 23, 2019 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced that management will be participating at the following upcoming investor conferences:
- Baird 2019 Global Healthcare Conference in New York, NY at 3:10 p.m. ET on Wednesday, September 4, 2019
- Citi 14th Annual Biotech Conference in Boston, MA at 12:45 p.m. ET on Thursday, September 5, 2019
Webcast information for these events will be available on the investor page of Intercept’s website at http://ir.interceptpharma.com. Archived webcasts will be available on Intercept’s website for approximately two weeks.
About InterceptIntercept is a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, including primary biliary cholangitis (PBC) and nonalcoholic steatohepatitis (NASH). Founded in 2002 in New York, Intercept has operations in the United States, Europe and Canada. For more information, please visit www.interceptpharma.com or connect with the company on Twitter and LinkedIn.
CONTACT
For more information about Intercept, please contact:
Justine O’Malley
+1-646-931-1180
Media inquiries: [email protected]
Source: Intercept Pharmaceuticals, Inc.Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Vita Pop: The Official & Exclusive Functional & Prebiotic Soda of the PPA Tour.
- Prince William County’s AI-Powered 311 Service Handles Nearly 40,000 Resident Conversations in First Year
- Innosphere Named One of America's Best Incubators & Accelerators of 2026 by TIME
Create E-mail Alert Related Categories
Globe Newswire, Press ReleasesRelated Entities
Citi, Robert W Baird, TwitterSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share